Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Central Nervous System Neoplasm;   ETV6 Gene Rearrangement;   Infantile Fibrosarcoma;   NTRK1 Fusion Positive;   NTRK1 Gene Rearrangement;   NTRK2 Fusion Positive;   NTRK2 Gene Rearrangement;   NTRK3 Fusion Positi ve;   NTRK3 Gene Rearrangement;   Recurrent Acute Leukemia;   Refractory Acute Leukemia;   Solid Neoplasm Intervention:   Drug: Larotrectinib Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials